The results of the in vivo experiments were also completely consistent with these results, and no statistical difference in the tumor mass or volume was detected between the two groups, which further demonstrated that GSDMB promoted the progression of bladder cancer by regulating STAT3. The gene discussed is STAT3; the disease is urinary bladder cancer.